Welcome to our dedicated page for Evaxion Biotech A/S American Depositary Share news (Ticker: EVAX), a resource for investors and traders seeking the latest updates and insights on Evaxion Biotech A/S American Depositary Share stock.
Evaxion Biotech A/S (symbol: EVAX) is a clinical-stage biotechnology company founded in 2008 with the mission to address some of the most significant global health challenges using artificial intelligence (AI). The company has developed robust platforms for creating novel vaccines and therapies. Evaxion's primary AI platforms, PIONEER and EDEN, utilize advanced in silico tools including big data, AI, and supercomputing to predict, rank, and optimize epitopes and antigens that stimulate highly protective immune responses against cancers and infectious diseases.
Evaxion's EDEN platform focuses on the rapid discovery of new antigens eliciting cross-protective immune responses against bacterial pathogens. On the other hand, the PIONEER platform identifies epitopes of mutated proteins to activate the body's natural immune responses. Additionally, the company has developed two more AI platforms, RAVEN and ObsERV, to further enhance its drug development pipeline.
The company's leading product candidates include EVX-01 and EVX-02, which are under development for cancer treatment, as well as EVX-03, a pre-clinical candidate for non-small-cell lung cancer (NSCLC). With a strong focus on AI-driven drug discovery and development, Evaxion aims to create innovative immunotherapies with improved efficacy for patients with unmet medical needs.
Recent news highlights key company activities, such as:
- A replay of the R&D Day presentations is available on the company's website.
- Information about the EVX-01 Phase 2 clinical trial.
- The company resolved a Nasdaq equity deficiency issue stemming from the IFRS accounting treatment of investor warrants.
To learn more about Evaxion Biotech A/S and its innovative AI-driven approaches, please visit Evaxion Biotech.
Evaxion Biotech (NASDAQ: EVAX) is in advanced discussions with the European Investment Bank (EIB) to convert €3.5 million of its €7 million loan into an equity-type instrument. The conversion is expected to increase Evaxion's equity by $3.7 million upon completion in Q1 2025. This strategic move aims to ensure compliance with Nasdaq listing requirements and strengthen the company's financial position.
As Evaxion's only debt is the EIB loan, the conversion would significantly reduce overall liabilities, simplify the balance sheet, and improve financial flexibility and cash flow. The terms under discussion are reported to be favorable for both the company and its shareholders.
Evaxion Biotech (NASDAQ: EVAX), a clinical-stage TechBio company, has achieved preclinical Proof-of-Concept (PoC) for its AI-Immunology™ platform, which designs precision cancer vaccines targeting non-conventional ERV tumor antigens. The new data, presented at the ESMO Immuno-Oncology Congress, confirm the approach's effectiveness by inducing strong T-cell responses and inhibiting tumor growth in mice.
The AI-Immunology™ platform identifies ERV fragments, or hotspots, that match diverse immune system profiles, potentially broadening the applicability of cancer vaccines to patients unresponsive to conventional immunotherapies. Evaxion plans to select a lead ERV precision vaccine candidate by the second half of 2025.
CEO Christian Kanstrup highlighted the milestone achievement, emphasizing the potential for improved treatment options leveraging AI-Immunology™ to design broadly applicable precision vaccines. The data from human cell and mouse model studies demonstrate the platform's capability to induce functional, antigen-specific T-cells and inhibit tumor growth.
Evaxion Biotech (NASDAQ: EVAX) has announced its strategic milestones for 2025 following the successful achievement of most 2024 goals. The company's key priorities include executing business development strategy, continuing the EVX-01 phase 2 trial, strengthening their AI-Immunology™ platform, and advancing research activities.
The 2025 milestones include: launching an automated lead vaccine candidate design module in H2, securing at least two new partnership agreements, completing EVX-01 patient dosing in H1, obtaining phase 2 clinical efficacy readout in H2, selecting a lead vaccine candidate for precision ERV cancer vaccines, potential MSD option exercise worth up to $10 million, selecting lead antigens for CMV vaccine candidate, and introducing two new pipeline candidates in infectious diseases.
Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage TechBio company, will present preclinical Proof-of-Concept for its precision cancer vaccine concept at the ESMO Immuno-Oncology Congress from December 11-13, 2024, in Geneva, Switzerland.
The data, derived from studies in human cells and mouse tumor models, highlight human T-cell responses and mouse tumor growth inhibition induced by the precision ERV (endogenous retrovirus) vaccine targets identified using Evaxion's AI-Immunology™ platform.
ERV antigens can be selected for precision therapeutic cancer vaccines, offering new treatments for various cancer types, including those unresponsive to conventional immunotherapy. This approach allows for designing vaccines effective across diverse immune system characteristics, suitable for a wide range of patients.
Evaxion will use this preclinically validated concept to design new precision vaccine candidates to enhance its existing pipeline.
Conference Details:
Abstract title: AI-designed cancer vaccines: antigens from the dark genome are promising cancer vaccine targets
Poster#: 124P
Location: Foyer Mezzanine
Date/Time: December 12, 2024, at 12.30 CET/06.30 EST
Presenter: Daniela Kleine-Kohlbrecher, Senior Project Manager at Evaxion
Evaxion Biotech (NASDAQ: EVAX) has received a delisting determination from Nasdaq due to failure to maintain stockholders' equity of at least $2.5 million. The company has appealed the decision and requested a hearing, seeking another 180-day extension to comply with Nasdaq's equity requirements. The appeal will suspend any trading suspension until the hearing process concludes. This follows a previous deficiency letter received on May 7, 2024, after which Evaxion was granted a 180-day extension that expired on November 4, 2024. The company plans to increase stockholder's equity through business development income and capital markets activities, though compliance cannot be guaranteed.
Evaxion reported positive preclinical data for its cytomegalovirus (CMV) vaccine program EVX-V1. The study demonstrated that CMV antigens identified using their proprietary AI-Immunology™ platform successfully triggered targeted immune responses. The results also validated their proprietary prefusion glycoprotein B (gB) antigen design, showing virus neutralization capabilities. Based on these findings, Evaxion is proceeding with the development of a multi-component CMV vaccine candidate.
Evaxion Biotech (NASDAQ: EVAX) announced Q3 2024 financial results and business updates. Key highlights include an expanded collaboration with MSD, positive phase 2 data for EVX-01 cancer vaccine showing 69% Overall Response Rate, and preclinical Proof-of-Concept for EVX-B2 mRNA Gonorrhea vaccine. Q3 revenue was $3.0 million compared to nil in Q3 2023. Net loss decreased to $1.9 million ($0.04 per share) from $5.7 million ($0.21 per share) year-over-year. Cash position was $4.6 million as of September 30, 2024, with runway into March 2025. The company faces Nasdaq compliance issues regarding minimum stockholder's equity requirements.
Evaxion Biotech (NASDAQ: EVAX), a clinical-stage TechBio company focused on AI-powered vaccine development, has scheduled its Q3 2024 financial results announcement and business update for October 31, 2024, before Nasdaq CM opening. The company's Executive Management will host a conference call and webcast at 13:30 CET/08:30 EST on the same day. The event is free and open to the public, with advance registration required for participation. A webcast recording will be made available on the company's website after the event.
Evaxion Biotech A/S (NASDAQ: EVAX) has reported strong validation of its AI-Immunology™ platform in multiple clinical trials. The company, specializing in AI-powered vaccine development, has gathered evidence from three separate clinical trials demonstrating the platform's ability to select clinically relevant vaccine targets.
Key findings include:
- Statistically significant correlation between AI-Immunology™ prediction scores and immunological responses in patients
- Strongest outcomes generated by top-ranked AI-Immunology™ vaccine targets
- In one trial, a statistically significant correlation between AI-Immunology™ prediction scores and Progression Free Survival (PFS)
The data supports the platform's potential in selecting effective vaccine targets and allows for continuous refinement of AI-Immunology™, broadening its commercial potential. Evaxion's CEO, Christian Kanstrup, emphasized the importance of generating relevant clinical data for the ongoing development of the platform.
Evaxion Biotech A/S (NASDAQ: EVAX) has reported significant improvements in its AI-Immunology™ platform's predictive power for clinically relevant vaccine targets. In the ongoing phase 2 trial of their personalized cancer vaccine EVX-01, 79% of the AI-predicted vaccine targets triggered a tumor-specific immune response, up from 58% in the phase 1 trial.
This improvement is attributed to iterative learning and integration of advanced bioinformatics and machine learning techniques. The company believes this enhanced precision boosts the potential of its AI-derived vaccine candidates and is important for clinical efficacy and commercial potential.
CEO Christian Kanstrup emphasized the importance of this progress, stating that the 79% response rate compares favorably to other personalized cancer neoantigen trials. He also noted that the strong clinical outcome data provides Evaxion with a compelling AI-Immunology™ derived investigational vaccine candidate.
FAQ
What is the current stock price of Evaxion Biotech A/S American Depositary Share (EVAX)?
What is the market cap of Evaxion Biotech A/S American Depositary Share (EVAX)?
What does Evaxion Biotech A/S specialize in?
What are the main AI platforms used by Evaxion Biotech?
What are Evaxion's leading product candidates?
What recent developments have taken place at Evaxion Biotech?
When was Evaxion Biotech A/S founded?
How does the EDEN platform contribute to Evaxion's research?
What is PIONEER platform's role in Evaxion's operations?
What kind of financial challenges has Evaxion recently addressed?
Where can I find more information about Evaxion's recent activities?
What is the mission of Evaxion Biotech A/S?
